• 1
    Levine PH, Steinhorn SC, Ries LG, et al. Inflammatory breast cancer: the experience of the Surveillance, Epidemiology, and End Results (SEER) Program. J Natl Cancer Inst. 1985; 74: 291297.
  • 2
    Chang S, Parker SL, Pham T, et al. Inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, 1975–1992. Cancer. 1998; 82: 23662372.
  • 3
    Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol. 1992; 10: 10141024.
  • 4
    Chevallier B, Bastit P, Graic Y, et al. The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients. Br J Cancer. 1993; 67: 594601.
  • 5
    Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997; 40: 321329.
  • 6
    Feldman LD, Hortobagyi GN, Buzdar AU, et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986; 46: 25782581.
  • 7
    Maloisel F, Dufour P, Bergerat JP, et al. Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer. 1990; 65: 851855.
  • 8
    Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998; 352: 930942.
  • 9
    French Epirubicin Study Group. A prospective randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J Clin Oncol. 1988; 6: 679688.
  • 10
    Italian Multicentre Breast Study with Epirubicin. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J Clin Oncol. 1988; 6: 976982.
  • 11
    Gisselbrecht C, Lepage E, Extra JM, et al. Cancer of the breast: intensive treatment with bone marrow autografts. Bull Cancer. 1989; 76: 99104.
  • 12
    Hansen R, Quebbeman E, Beatty P, et al. Continuous 5-fluorouracil infusion in refractory carcinoma of the breast. Breast Cancer Res Treat. 1987; 10: 145149.
  • 13
    Chevallier B, Roche H, Olivier JP, et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993; 16: 223228.
  • 14
    Chevallier B, Chollet P, Merrouche Y, et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol. 1995; 13: 15641571.
  • 15
    Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames: Iowa State University Press, 1980.
  • 16
    Duncan DB. P-tests and intervals for comparison suggested by the data. Biometrics. 1975; 31: 339359.
  • 17
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1985; 53: 229232.
  • 18
    Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc A. 1972; 135: 185198.
  • 19
    Cox DR. Regression models and life-tables. J R Stat Soc B. 1972; 34: 187202.
  • 20
    Harris EER, Schultz D, Bertsch H, et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2003; 55: 12001208.
  • 21
    Bauer RL, Busch E, Levine E, Edge SB. Therapy for inflammatory breast cancer: impact of doxorubicin-based therapy. Ann Surg Oncol. 1995; 2: 288294.
  • 22
    Attia-Sobol J, Ferriere JP, Cure H, et al. Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: univariate and multivariate analysis. Eur J Cancer. 1993; 29A: 10811088.
  • 23
    Palangie T, Mosseri V, Mihura J, et al. Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer. 1994; 30A: 921927.
  • 24
    Colozza M, Gori S, Mosconi AM, et al. Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long-term results. Am J Clin Oncol. 1996; 19: 1017.
  • 25
    Thomas F, Arriagada R, Spielmann M, et al. Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy. Cancer. 1995; 76: 22862290.
  • 26
    Tubiana-Mathieu N, Lejeune C, Bonnier P, et al. Chemotherapy and concomitant irradiation in inflammatory breast cancer. Anticancer Res. 2001; 21: 30613067.
  • 27
    Brun B, Otmezguine Y, Feuilhade F, et al. Treatment of inflammatory breast cancer with combination chemotherapy and mastectomy versus breast conservation. Cancer. 1988; 61: 10961103.
  • 28
    Bertucci F, Tarpin C, Charafe-Jauffret E, et al. Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment. Bone Marrow Transplant. 2004; 33: 913920.
  • 29
    Arun B, Slack R, Gehan E, et al. Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma. Cancer. 1999; 85: 9399.
  • 30
    Perez CA, Fields JN, Fracasso PM, et al. Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma. Cancer. 1994; 74( Suppl 1): 466476.
  • 31
    De Boer RH, Allum WH, Ebbs SR, et al. Multimodality therapy in inflammatory breast cancer: is there a place for surgery? Ann Oncol. 2000; 11: 11471153.
  • 32
    Hagelberg RS, Jolly PC, Anderson RP. Role of surgery in the treatment of inflammatory breast carcinoma. Am J Surg. 1984; 148: 125131.
  • 33
    Fleming RY, Asmar L, Buzdar AU, et al. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol. 1997; 4: 452461.
  • 34
    Thoms WWJr., McNeese MD, Fletcher GH, et al. Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 1989; 17: 739745.
  • 35
    Arthur DW, Schmidt-Ullrich RK, Friedman RB, et al. Accelerated superfractionated radiotherapy for inflammatory breast carcinoma: complete response predicts outcome and allows for breast conservation. Int J Radiat Oncol Biol Phys. 1999; 44: 289296.
  • 36
    Fein DA, Mendenhall NP, Marsh RD, et al. Results of multimodality therapy for inflammatory breast cancer: an analysis of clinical and treatment factors affecting outcome. Am Surg. 1994; 60: 220225.
  • 37
    Giordano SH. Update on locally advanced breast cancer. Oncologist. 2003; 8: 521530.
  • 38
    Ayash LJ, Elias A, Ibrahim J, et al. High-dose multimodality therapy with autologous stem-cell support for Stage IIIB breast carcinoma. J Clin Oncol. 1998; 16: 10001007.
  • 39
    Viens P, Palangie T, Janvier M, et al. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer. 1999; 81: 449456.
  • 40
    Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, et al. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2004; 4: 415419.
  • 41
    Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003; 21: 41654174.
  • 42
    Hutcheon AW, Heys SD, Sarkar TK, et al. Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial [abstract 11]. 26th San Antonio Breast Cancer Symposium, San Antonio, Texas, December 3–6, 2003.
  • 43
    Pedersen-Bjergaard J, Philip P. Two different classes of therapy-related and de-novo acute myeloid leukemia? Cancer Genet Cytogenet. 1991; 55: 119124.
  • 44
    Smith RE, Bryant J, DeCillis A, et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol. 2003; 21: 11951204.
  • 45
    Bergh J, Wiklund T, Erikstein B, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet. 2000; 356: 13841391.
  • 46
    Aziz SA, Pervez S, Khan S, et al. Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience. Breast J. 2001; 7: 398404.
  • 47
    Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci. 2002; 27: 462467.
  • 48
    van Golen KL, Wu ZF, Qiao XT, et al. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 2000; 60: 58325838.
  • 49
    van Golen KL, Bao L, DiVito MM, et al. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther. 2002; 1: 575583.